BioSphere Medical, Inc. Fourth Quarter Results Feature 24% Growth in U.S. Revenue for Embolics and Delivery Systems

ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere” or the “Company”) – a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported its financial results for the three and 12 months ended December 31, 2008. Highlights of the fourth quarter and recent weeks include: